Medable Inc., a technology provider for clinical trials, introduced a new automation technology applied across its clinical trials platform that is designed to cut standard trial build timelines.

By automating manual tasks such as testing, Medable’s new technology aims to save time and remove electronic clinical outcomes assessment (eCOA) from the critical path to trial go-live. With new AI and automations capabilities, the technology aims to eliminate common gridlocks caused by conversion, configuration, validation, and quality engineering.

Medable’s updated eCOA capabilities include an auto-configuration tool that produces standard configurations, such as schedules of assessments, anchor dates, and patient flags. Medable’s auto-validate tool is designed to automatically deliver a downloadable configuration validation report (CVR) that validates the quality of study builds.

“We are reimagining the way clinical trials are deployed by eliminating many of the biggest process bottlenecks,” said Michelle Longmire, CEO, and co-founder of Medable. “Starting with eCOA, we are accelerating clinical trials while helping to improve data quality – ultimately enabling our vision of a one-day study start-up to help deliver effective treatments and cures to patients faster. In 2024, expect to see more innovative technologies and new ways of delivering streamlined, patient-centric trials from Medable.”